Zika virus congenital syndrome

Summary

Zika virus congenital syndrome (MONDO:0000890) is a disease with 1 GWAS associations across 1 studies and 2 clinical trials. A subtype of viral infectious disease — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

At a glance

• GWAS associations: 1
• Clinical trials: 2

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

Field	Value
Canonical name	Zika virus congenital syndrome
Mondo ID	MONDO:0000890
DOID	DOID:0080180
ICD-11	755611612
UMLS	C4546023
MedGen	1622152
GARD	0013441
Is cancer (heuristic)	no

Also known as: congenital Zika syndrome · congenital Zika virus infection

Data availability: 1 GWAS association (1 study).

Disease family

This is a subtype of viral infectious disease. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.

Classification path: disease › human disease › disease by etiologic mechanism › disease of primarily extrinsic mechanism › infectious disease › viral infectious disease › Zika virus congenital syndrome

Related subtypes (40): Whitewater Arroyo hemorrhagic fever, exanthema subitum, common wart, viral labyrinthitis, viral gastritis, vaccinia, viral esophagitis, Kaposi’s sarcoma, contagious pustular dermatitis, epidemic pleurodynia, herpangina, human T-lymphotropic virus 1 infectious disease, lumpy skin disease, milker’s nodule, molluscum contagiosum, Newcastle disease, pharyngoconjunctival fever, pseudorabies, Reoviridae infectious disease, immunodeficiency 32B, focal epithelial hyperplasia, neurolymphomatosis, viral myositis, virus-associated trichodysplasia spinulosa, infective dermatitis associated with HTLV-1, congenital varicella syndrome, viral hemorrhagic fever, arbovirus fever, human infection by orthopoxvirus, congenital Epstein-Barr virus infection, rabies, arbovirus infection, viral eye infection, viral infection of central nervous system, viral respiratory tract infection, Parvoviridae infectious disease, COVID-19–associated multisystem inflammatory syndrome in children, primary viral infectious disease, disease arising from reactivation of latent virus, human betaherpesvirus 5 infectious disease

Genetics & variants

GWAS landscape

1 GWAS associations across 1 studies. Top hits map to 1 distinct genes (as reported by GWAS).

Top associations by p-value

rsID	p-value	Gene	Risk allele	Odds ratio
rs2076469	3e-06	DISP3	G	0.01

Top studies (by case count)

Study	Lead author	Year	Cases	Controls	Title
GCST90093463	Borda V	2021	29	0	Whole-exome sequencing reveals insights into genetic susceptibility to Congenital Zika Syndrome.

Variant details and genetic-evidence tiers

Tier distribution (top 50 variants)

Tier	Variants
Tier 1: coding	0
Tier 2: splice/UTR	0
Tier 3: regulatory	0
Tier 4: intronic/intergenic	1

MAF distribution

Bucket	Variants
common (>=0.05)	1
low_freq (0.01-0.05)	0
rare (<0.01)	0
unknown	0

Functional consequences

Consequence	Count
intron_variant	1

Top variants

rsID	Chr	Pos	Alleles	MAF	Consequence	Gene	p-value	Tier
rs2076469	1	11524107	A>G,T	0.14	intron_variant	DISP3	3e-06	Tier 4: intronic/intergenic

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

No druggable-target or therapeutic data for this disease’s cohort.

Clinical trials & evidence

Clinical trials

Clinical trials: 2.

Phase distribution (across all retrieved trials)

Phase	Trials
Not specified	2

Top trials by phase / activity

NCT	Phase	Status	Title
NCT04398901	Not specified	ENROLLING_BY_INVITATION	Neurodevelopmental Outcomes in ZIKV-Exposed Children
NCT06900322	Not specified	COMPLETED	Impacts of a Physical Therapy Protocol on Motor Function in Children With Congenital Zika Syndrome